Skip to main content

Sophia Genetics Providing NHS, Turkish Lab Access to Bioinformatics Platform

NEW YORK (GenomeWeb) – Bioinformatics firm Sophia Genetics today announced deals with the UK's National Health Service and an unnamed Turkish laboratory to provide them access to the company's data-driven medicine platform.

The platform offers a secure software-as-a-service module for the analysis, validation, quality control, and presentation of genetic tests to clinicians, as well as storage and data sharing capabilities.

Lausanne, Switzerland-based Sophia said that it has developed algorithms based on machine learning and iterative Bayesian mathematics for an unbiased view of the data.

"As next-generation sequencing becomes more common, we are seeing more oncologists and clinicians demand the degree of accuracy and readability that Sophia Genetics offers, and we take pride in the fact that we provide them with unique reports they can act on immediately," Sophia CEO Jurgi Camblong said in a statement.

Last week, the company announced it obtained the CE-IVD mark for its next-generation sequencing bioinformatics pipeline for routine genetic testing. Earlier in the summer it said that it raised $13.75 million in a Series B financing round.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.